These are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information. For more information, please see our FAQs.
Virtual Screening of Leishmanial Pyridoxal Kinase Enzyme Inhibitors by Repurposed Anti-Trypanosomal Libraries Reveals Two Core Scaffolds
preprintsubmitted on 10.10.2020, 19:58 and posted on 13.10.2020, 05:22 by Sanad Alfadhel
Leishmania is an intracellular protozoal infection, and it is classified as a neglected disease by the World Health Organization (WHO). Annually more than 2 million newly diagnosed cases were treated with highly toxic drugs. Leishmanial pyridoxal kinase enzyme (LPDxK) is an essential and druggable target. DNDI1103666 is the most promising lead as a potential inhibitor for LPDxK